SCHEMBL8071397

SCHEMBL8071397

CC(C)(C)OC(=O)C(Cc1ccccc1)C(N)=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGA4 P13612 1/20 0.48
ITGB7 P26010 1/20 0.48
EPHX1 P07099 1/20 0.46
ATM Q13315 1/20 0.46
MMP8 P22894 1/20 0.46
MDM2 Q00987 1/20 0.45
POLB P06746 1/20 0.44
MAPT P10636 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
CTSS P25774 2/20 0.44
CTSL P07711 1/20 0.44
CTSB P07858 1/20 0.44
CTSK P43235 1/20 0.44
SLC7A5 Q01650 1/20 0.44
PPARG P37231 1/20 0.43
PPARD Q03181 1/20 0.43
PPARA Q07869 1/20 0.43
SRR Q9GZT4 1/20 0.42
REN P00797 1/20 0.42
ACE P12821 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5711183 1.00 ITGA4 (0.48) ITGA4ITGB7EPHX1ATMMMP8
SCHEMBL9160311 0.90 ITGA4 (0.52) ITGA4ITGB7ATMMMP8MDM2
SCHEMBL1595571 0.89 ITGA4 (0.51) ITGA4ITGB7ATMMMP8MDM2
SCHEMBL4909735 0.89 ITGA4 (0.51) ITGA4ITGB7ATMMMP8MDM2
SCHEMBL1595565 0.89 ITGA4 (0.51) ITGA4ITGB7ATMMMP8MDM2
SCHEMBL6464419 0.86 ITGA4 (0.47) ITGA4ITGB7ATMMMP8MDM2
SCHEMBL28837745 0.85 ITGA4 (0.46) ITGA4ITGB7EPHX1ATMMMP8
SCHEMBL28598197 0.85 CTSS (0.45) EPHX1CTSSCTSKPPARG
SCHEMBL17202990 0.84 ITGA4 (0.54) ITGA4ITGB7ATMMMP8MDM2
SCHEMBL9556107 0.83 MMP8 (0.62) ITGA4ITGB7ATMMMP8MDM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE36718-E 3-AMINO-1-NITRO-4-PHENYL-2-BUTANOL DERIVATIVES KANEKA CORPORATION (JP) 2000-05-30 US claimed
US-5616726-A AN 3-AMINO-1-NITRO-4-PHENYL-2-BUTANOL BY ADDING NITROMETHANE STEREOSELECTIVELY IN THE PRESENCE OF A BASE TO AN OPTICAL ACTIVE AMINOALDEHYDE; CHEMICAL INTERMEDIATES FOR DRUGS; E.G. THE ANTICARCINOGENIC AGENT, BESTATIN KANEKA CORPORATION (JP) 1997-04-01 US claimed
EP-0657415-A1 OPTICALLY ACTIVE AMINO ALCOHOL DERIVATIVE AND PROCESS FOR PRODUCING THE SAME KANEKA CORPORATION (JP) 1995-06-14 EP claimed
US-20150344404-A1 PDK4 INHIBITOR AND USE THEREOF THE KITASATO INSTITUTE (JP) 2015-12-03 US disclosed
EP-2939668-A1 PDK4 INHIBITOR AND USE THEREOF The Kitasato Institute (JP) 2015-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150344404-A1 PDK4 INHIBITOR AND USE THEREOF PDK4, PDK3, PDK2 ITGA4 3861/4885ITGB7 4474/4885EPHX1 1748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.